Analysis of efficacy, safety and prognostic factors of DAC‑HAA treatment in Chinese pediatric patients with refractory or relapsed acute myeloid leukemia
Affiliations: Children's Hematology Oncology, Anhui Provincial Cancer Hospital, Hefei, Anhui 230031, P.R. China, Department of Pediatrics, The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui 230001, P.R. China
- Published online on: November 1, 2021 https://doi.org/10.3892/mco.2021.2431
- Article Number: 269
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.